These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20577875)

  • 1. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
    Marshall R; Atuah KN; Tekumalla SH
    Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 7. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019.
    Kohama M; Nonaka T; Uyama Y; Ishiguro C
    Ther Innov Regul Sci; 2023 Jan; 57(1):37-47. PubMed ID: 35963930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
    Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
    Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post-marketing drug safety-risk management plan(RMP)].
    Ezaki A; Hori A
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):279-84. PubMed ID: 23507587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post-approval in Japan.
    Saito R; Miyazaki S
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01110. PubMed ID: 37365794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current situation and issues regarding termination of risk management plans in Japan.
    Kameyama N; Hosaka A; Maeda H
    Front Med (Lausanne); 2024; 11():1387652. PubMed ID: 38873195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction to risk management plans in the Singapore context.
    Ho CSC; Tan LLB; Chan CL
    Singapore Med J; 2019 Sep; 60(9):483-486. PubMed ID: 31570951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.